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Background: The combination of rituximab and 2-CdA is an effective therapy for B-cell tumors. However, the
molecular mechanisms and enzymatic pathways involved in the interaction between the two agents are not fully
understood. In this study, we provide molecular evidence for positive interaction between these two agents with
resultant therapeutic benefit.
Methods: Efficacy of the R-2CdA regimen was evaluated in thirteen patients with B-cell tumors (9 CLL; 3 WM and 1
FL), in vitro against 3 lymphoma cell lines and in a xenograft mouse model. Treatment-induced changes involving
phenotype, kinase activity and protein expression were assessed in vitro and in the mouse xenograft tumors. The
interaction between RTX and 2-CdA was analyzed using the multiple comparison method, Tukey’s honestly
significant difference (HSD). For the clinical and animal data, survival functions were estimated using the
Kaplan-Meier method and compared by the log-rank test. P-values <0.05 were considered statistically significant.
All statistical analyses were evaluated using GraphPad Prism 4 (San Diego, CA).
Results: 9 of 12 (75%) evaluable patients responded to the R-2-CdA regimen with median duration of response of
34 months. Median survival of patients from diagnosis and from completion of R-2-CdA treatment was 13.3 and
7.9 years, respectively. In vitro, the combination was effective in all 3 cell lines of lymphomas but with higher
sensitivity in the follicular lymphoma cell line. The combination was also effective in the WSU-WM-SCID xenograft
model with dose-dependent response and synergistic benefit. All animals were tumor-free for up to 120 days post
2 cycles of this regimen. Rituximab induced activation of deoxycytidine kinase (dCK), p38 mitogen activated protein
kinase (p38MAPK) and glycogen synthase kinase-3β (GSK-3β) in the xenograft WSU-WM tumors. Chemical inhibition
of p38MAPK led to inhibition of the GSK-3β phosphorylation suggesting that GSK-3β is regulated by p38MAPK in
this model.
Conclusion: Collectively, our studies show concordance between the activity of R-2-CdA in vitro, in human and in
WSU-WM xenograft model attesting to the validity of this model in predicting clinical response. Modulation of dCK
and GSK-3β by rituximab may contribute to the positive therapeutic interaction between rituximab and 2-CdA.
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The anti-CD20 antibody (Rituximab, RTX) represents
the most significant advancement in the treatment of B-
cell lymphoma and chronic lymphocytic leukemia in the
past 30 years [1]. It has activity as single agent in re-
lapsed low-grade follicular lymphoma (FL) which was
the basis for its approval by the US Food and Drug
Administration (FDA) as therapeutic agent for FL [2]. It
has also been shown to prolong progression-free survival
of FL patients when used in different maintenance pro-
grams following initial chemotherapy [3-6]. The most
significant contribution of this agent, however, was its
ability to enhance the anti-lymphoma effects of cytotoxic
chemotherapy regimens used in the treatment of B-cell
lymphoma. Although its initial approval was in FL, it
was found to enhance efficacy of chemotherapy in all
major types of B-cell lymphoma including FL, diffuse
large B-cell lymphoma (DLBCL) and mantle cell lymph-
oma (MCL) [7]. Since the concept of combining RTX
with cytotoxic chemotherapy agents was introduced [8],
RTX-chemotherapy combinations have become a stand-
ard of care for B-cell lymphoma world-wide [9-11]. Re-
cent data has shown that even transformed low grade
lymphoma known to have very poor prognosis, has im-
proved outcome in the rituximab era [12].
Despite its proven activity, the mechanisms of action
of RTX are not fully understood. Direct signaling,
complement-dependent cytotoxicity (CDC) and antibody-
dependent cell-mediated cytotoxicity (ADCC) all appear
to play a role in RTX anti-lymphoma effect [13]. Each of
these mechanisms appears to be differentially more im-
portant in different settings depending on cell type, im-
mune system status and other factors [14]. Direct binding
of RTX to CD20 triggers a number of signaling pathways
including apoptosis, activation (or downregulation) of
protein kinases, phosphatases and caspases [15]. However,
the molecular basis for chemotherapy-enhancing effect of
RTX remains largely unknown.
In this study, we analyzed the activity of the R-2-CdA
regimen where RTX (R) is given in combination with
2-chlorodeoxyadenosine (2-CdA) in patients with low
grade B-cell tumors, in a mouse xenograft model for
human Waldenstrom’s macroglobulinemia and in vitro
studies. The nucleoside analogue 2-CdA as single agent
has activity in low grade non-Hodgkin’s lymphoma (NHL)
and in chronic lymphocytic leukemia/small lymphocytic
lymphoma (CLL/SLL) when used as first line therapy
[16,17] or as ‘salvage’ therapy following relapse of disease
[18]. This agent has also been used in combination with
RTX alone or with RTX plus other agents such as
cyclophosphamide [19-21] with superior results to that of
2-CdA alone [22-24].
Results of studies reported here reveal that R-2-CdA
regimen has significant activity in relapsed low gradeNHL. Moreover, we present evidence to show that RTX
can modulate specific protein kinases such as deoxycyti-
dine kinase (dCK) and glycogen synthase kinase 3β
(GSK3β) which are new findings. We also demon-
strated that p38 mitogen-activated protein kinase (p38
MAPK) can regulate GSK3β. These findings provide
some insight into the mechanisms of RTX-induced
enhancement of chemotherapy effects.
Material and methods
Clinical study
We retrospectively reviewed records on 13 patients who
were treated with 2-CdA and RTX combination (R-2-
CdA) at the Van Elslander Cancer Center during the
period of January 2005-January 2013. The study was ap-
proved by St. John Hospital & Medical Center’s institu-
tional review board. Patient selection was based on
medical records showing use of R-2-CdA combination
therapy in patients with B-Cell lymphoma. Primary end
points of the study were response rate, response duration
and survival. Secondary endpoints included toxicity of the
regimen. Rituximab was administered intravenously (iv)
on day one using standard dose of 375 mg/m2 and a
standard protocol. Patients were premedicated with acet-
aminophen (1000 mg orally X1), diphenhydramine (Bena-
dryl®) iv at a dose of 25 mg repeated if necessary, and
methylprednisolone sodium succinate, USP (Solu-medrol®)
iv at a dose of 125 mg repeated if necessary for rituximab-
related infusion reaction. Rituximab infusion was initiated
at a low rate of 50 mg/m2 and doubled every thirty mi-
nutes, to a maximum rate of 400 mg/m2 provided there
were no adverse reactions and patient’s vital signs were
stable. At the completion of rituximab infusion on day 1, a
2-CdA pump was hooked up to a central venous access
(MediPort) and 2-CdA was delivered at a dose of 0.1 mg/
kg/day as continuous infusion for 7 consecutive days. The
treatment was repeated in 28-day cycles but delayed when
necessary to allow for recovery of cell counts or other
toxicities. In one patient, however, 2-CdA was delivered
subcutaneously due to lack of venous access. In another
patient, 2-CdA was delivered daily over 5 days as iv infu-
sion over 2 hours according to Nagai et al. [25]. Toxicity
was graded according to the US National Cancer Institute
using the Common Terminology Criteria for Adverse
Events (CTCAE) version 4.03. In general, toxicity is graded
as mild (grade 1), moderate (grade 2), severe (grade 3) or
life threatening (grade 4). Death is considered grade 5.
In vitro studies
Cell lines
The WSU-WM, WSU-DLCL2 and the WSU-FSCCL cell
lines, used in this study, were established at Wayne State
University (WSU) and their characteristics have been pre-
viously published [26-29]. The WSU-WM was established
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WSU-DLCL2 represents diffuse large B-cell lymphoma
(DLBCL), and WSU-FSCCL was established from a pa-
tient with follicular lymphoma, grade 1 according to the
current World Health Organization (WHO) classification.
All three cell lines are EBV negative and are maintained
in a liquid culture medium consisting of RPMI 1640
supplemented with 10% fetal bovine serum (FBS), 1% L-
glutamine and 1% penicillin-streptomycin. The pheno-
typic and cytogenetic characteristics of the cell lines are
checked periodically to determine stability.
Cell growth and viability
WSU-WM, WSU-FSCCL and WSU-DLCL2 cells were
seeded at 2.0 × 105 cells/ml in a 24 well plate (in tripli-
cate). 2-CdA (50 nM), RTX (100 μg) individually or in
combination were added to respective wells. Cultures
were incubated for 96 h at 37°C and 5% CO2. Viability
and growth inhibition were determined each day using
0.4% trypan blue (Sigma) exclusion.
Inhibition of p38MAPK using SB203580
WSU-WM cells were seeded at 1 × 106 cells/5 ml in T25
flask (in triplicate). 2-CdA (50 nM), RTX (100 μg) or ve-
hicle (DMSO and RPMI 1640 medium) added to re-
spective flasks. Cultures were incubated for 96 h at 37°C
and 5% CO2. After 48 h 2-CdA or RTX treatment,
p38MAPK specific inhibitor, SB203580 (Selleck Chemicals,
USA) was added at 30 μM. Cells were counted at 72 h
and 96 h in the presence or absence of inhibitor. At
selected time points, cells were collected and protein
expression was evaluated by Western blot analysis as
described below.
Western blotting
Control and drug-treated WSU-WM cells were soni-
cated and collected by centrifugation, washed twice with
sterile PBS, and solubilized in RIPA lysis buffer (Ther-
moScientific, Rockford, IL) consisting of a cocktail of
protease and phosphatase inhibitors. Total cell protein
was quantified by BCA method (Pierce; Thermo Scien-
tific). 50 μg aliquots of protein were fractionated onto 4-
20% Tris-Glycine SDS-PAGE gels, then transferred onto
PVDF membrane. Membranes were blocked in PBS with
5% (w/v) fat-free milk powder and probed with primary
antibodies to p-p38MAPK (Thy 182) and p-GSK3β (Ser
9) (Cell signalling Technology, Danvers, MA). GAPDH
(Sigma) was used as the internal control. The secondary
antibodies were anti-mouse or anti-rabbit conjugated to
HRP (Jackson ImmunoResearch). After further extensive
washing in PBS-T, the blots were developed using en-
hanced chemiluminescence substrate reagents (Thermo
Scientific).Pre-clinical in vivo studies
WSU-WM-SCID mouse xenograft model This sub-
cutaneous model was initiated by injecting WSU-WM
cells (107) subcutaneously (sc) into the flank areas of
3–4 week old mice with severe combined immune defi-
ciency (SCID) as previously described [26,27]. Palpable
tumors developed in about 2 weeks. Tumors were prop-
agated serially in-vivo by transplanting tumor fragments
into the flanks of a new batch of animals. CB17 and ICR
SCID mice (Taconic Farms, Germantown, NY) have
both been used with equal success for in-vivo WSU-
WM tumor growth. No preconditioning of animals with
radiation or cyclophosphamide was necessary prior to
transplantation. Animals were kept in a protected en-
vironment and were euthanized when tumor weight
reached ~2000 mg (~10% of body weight) to avoid
animal discomfort. All animal experiments were done
according to Institutional Animal Care and Use Com-
mittee (IACUC)-approved protocol of WSU.Pre-clinical efficacy trial studies
WSU-WM tumor fragments were transplanted sc bilat-
erally into the flanks of ICR-SCID mice as described
above. Once palpable tumors were established, animals
were removed randomly and assigned to different inter-
ventions: Control (PBS); RTX; 2-CdA; and RTX plus
2-CdA. Two different experiments were conducted se-
quentially with different endpoints and doses as de-
scribed below:Experiment 1 In this experiment, 40 ICR-SCID mice
bearing subcutaneous WSU-WM tumors in both flanks,
developed as above, were used. Groups of 10 animals
were removed randomly and assigned to different inter-
ventions: Control; RTX; 2-CdA; and RTX plus 2-CdA.
RTX was administered iv via tail vein daily (QD) X 5
consecutive days (1–5) at 40 mg/kg/day. 2-CdA was ad-
ministered concurrently at 20 mg/kg/day, sc QD, days
1–5. The combination group received both agents at the
same dose and route, ie: RTX at 40 mg/kg/day iv and
2CdA at 20 mg/kg/day sc both given days 1–5. Treat-
ment began 7 days after tumor implantation. Three ani-
mals out of each group were randomly selected and
tumors removed for analysis by Western blotting and
flow cytometry as described below. For the remaining 7
animals in each group, survival was the endpoint of
study. To determine survival, animals were monitored
for tumor growth and toxicity. Tumor-bearing animals
were euthanized when total palpable tumor weight
approached or exceeded 2000 mg (~10% of the body
weight) to avoid discomfort. Survival is calculated as the
interval (in days) between first day of treatment and day
of euthanasia. The experiment was terminated at day 80
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not they were carrying tumors.
Experiment 2 The design of the second experiment was
to evaluate the efficacy of increased dose of RTX, 2-CdA
and the combination in the WSU-WM model. In this
experiment, 32 ICR-SCID mice were utilized. WSU-WM
tumor fragments were transplanted sc as above. Animals
were randomly assigned to one of 4 groups, 8 animals
each: Control, RTX, 2-CdA and RTX plus 2-CdA. Treat-
ment began 7 days after tumor implantation. RTX was
administered iv through tail vein daily for 5 days at
150 mg/kg/day. 2-CdA was administered at 30 mg/kg/
day, sc QD x 5. The 2-CdA dose used here is the max-
imum tolerated dose (MTD) in SCID mice as previously
determined in our laboratory [30]. The RTX dose and
schedule were based on previously published work from
our laboratory [21]. The combination treatment group
received the same doses of RTX and 2-CdA daily for
5 days followed by one week rest and a second cycle of
same doses. End points of this experiment were tumor
response and 120-day tumor-free survival. The National
Cancer Institute (NCI) criteria for anti-tumor activity were
used for drug efficacy assessment. Tumor weights were es-
timated from two-dimensional measurements: Tumor
weight (mg) = (A × B2)/2, where “A” and “B” are the tumor
length and width in mm respectively. Tumor growth inhib-
ition (T/C) is the median tumor weight of the treated group
(T) divided by the median tumor weight of the control
group (C) at a time when the median tumor weight in the
control group reached approximately 700 mg. Tumor
growth delay (T-C) is the difference between the median
time, in days, required for the treatment group tumor (T)
to reach 900 mg and the median time in days for the con-
trol group tumor (C) to reach the same weight. The Log10
tumor cell kill total (gross) = (T-C)/ (3.32) (Td) where Td is
the time in days required for the tumor to double its weight
during the exponential growth phase. Cure is defined as
mice being tumor-free for 120 days after therapy.
Phenotypic analysis of WSU-WM-SCID xenografts by flow
cytometry
Six female ICR-SCID mice (Taconic Farms, Germantown,
NY), 3–4 weeks old were transplanted subcutaneously
bilaterally with tumor fragments (20–30 mg pieces) of
WSU-WM tumor as described above. One week later,
when palpable tumors developed (~140 mg), mice were
randomly separated into two groups of equal tumor bur-
den. Group 1 was treated with RTX at 150 mg/kg/injec-
tion (via tail vein, daily for 5 days). Group 2 (control)
received diluent for 5 days. Three days post last injection,
animals in treated group that had developed re-growth of
tumors after initial shrinkage were euthanized, their tu-
mors removed and dissected into single cell suspension,then subjected to phenotypic analysis by flow cytome-
try. For each RTX-treated animal studied, similarly
processed tumors from diluent-treated animals were
analyzed as control. One hundred μl of each tumor
cell suspension (approximately 1 × 106 cells/ml) were
placed into 12 × 75 plastic tubes, washed three times
with 1% BSA-PBS. Supernatant was decanted, FITC- conju-
gated primary mouse anti-human antibodies were added to
each tube. Cells were then washed after 30 minutes of
incubation in the dark at 4°C before analysis using
FACScan. Results were compared with tumors ob-
tained from the control group. The following antibodies
were purchased from DAKO Corporation (Carpenteria,
CA) anti -CD19, −CD20, −CD10, −CD22, −IgM, −lambda, −
CD55, −CD59. For anti-Rituximab staining, the same pro-
cedures were applied using anti-C2B8 antibody (clone
directed against Rituximab antibody) generously provided
by Genentech Corp (San Francisco, CA).
dCK assay
For these experiments, 18 WSU-WM tumor-bearing SCID
mice were separated into 3 groups. Within each group of 6
animals, 3 received 1, 3, or 5 daily injections of RTX and
the other 3 received diluent (as control). At the end of the
treatment, animals were euthanized, tumors dissected and
mechanically dissociated into single cell suspension using
steel mesh. After washing, cells were processed for dCK
enzyme activity assay as previously described [30]. Briefly,
harvested cells were washed with PBS × 2, aliquoted at a
concentration of 107 cells/ml/sample in sonication buffer
(50 mM Tris, 2 mM DTT, 0.5 mM PMSF, 10% Glycerol
and 40 ml deionized H20) and stored at -80°C until assayed.
DCK was determined using [8-3H]-2-CdA as a substrate
and dCK activity was calculated as pmol of phosphorylated
2-CdA generated per mg protein per minute.
Statistical analysis
For all cell line experiments, data were compiled from at
least three independent triplicate experiments performed
on separate cultures. The interaction between RTX and
2-CdA was analyzed using the multiple comparison
method called Tukey’s honestly significant difference
(HSD). Statistical significance (P < 0.05) id denoted on
graphs as *. For the clinical data and animal experiments,
survival functions were estimated using the Kaplan-Meier
method and compared by the log-rank test. P-values <0.05
were considered significant. All statistical analyses were
evaluated using GraphPad Prism 4 (San Diego, CA).
Results
Efficacy of R-2-CdA in Patients with indolent B-cell
tumors
Thirteen patients were included in this study between
January 2005 and January 2013. As shown in Table 1,
Table 1 Clinical data
Patient demographics
Total number of patients 13
Male: Female 7:6
Median Age at Diagnosis in years (range) 48 (39–71)
Median Age at R-2CdA treatment (range) 59 (40–76)
Histology
Chronic lymphocytic leukemia/small 9
Lymphocytic lymphoma (CLL/SLL)
Waldenstrom’s Macroglobulinemia (WM) 3
Follicular lymphoma Grade I/II 1
Stage
Rai Stage IV 6/8




Median number of prior regimens (range) 3 (2–7)
Response
Total response rate (RR) (number/percent) 10/13 (77%)
Complete response (CR) 7/13 (54%)
Partial response (PR) 3/13 (23%)
Progressive disease (PD) 3/13 (23%)
Median duration of response (range) 34 months (8-118+)
Common toxicity Grade
Total % 1 2 3 4
Anemia 8 (62%) 6 1 1
Thrombocytopenia 8 (62%) 5 1 2
Neutropenia 7 (54%) 2 3 2
Fatigue 7 (54%) 2 3 2
Weight loss 5 (38%) 3 2
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sis was 48 (Range: 39–71), while the median age at time
of R-2-CdA treatment was 59 (Range 40–76). Nine pa-
tients had a diagnosis of SLL/CLL; 3 were WM and one
with follicular lymphoma grade 1/2. All patients except
the follicular lymphoma patient were previously treated
with standard therapy consisting of rituximab and cyto-
toxic chemotherapy. (Median = 3 regimens, range 2–7).
Patients received a median of 2 cycles of R-2-CdA
therapy (range, 1–5 cycles). Seventy seven percent (10/
13 patients) responded; seven (54%) with complete re-
sponse (CR) and 3 (23%) with partial response (PR); the
remaining 3 patients had progressive disease (PD). The
median duration of response to R-2-CdA therapy was
34 months (range 8-118+). Overall survival from diagno-
sis to death or last follow up was 13.3 years and survival
from cessation of R-2-CdA treatment was 7.9 years(Figure 1). Major toxicity was hematologic (Table 1),
however, weight loss and fatigue were also common.
There were no treatment-related deaths.
In vitro cytotoxicity
The three lymphoma cell lines used represent the
spectrum of B-cell lineage tumors: (a) WSU-WM (plasma-
cytoid type); (b) WSU-FSCCL (follicular low grade lymph-
oma); (c) WSU-DLCL2 (diffuse large B-cell lymphoma). In
all three cell lines, exposure to both agents individually
and in combination caused progressive decrease in viable
cells in culture over a period of 72 h (Figure 2). The
WSU-FSCCL cells were the most sensitive where s signifi-
cant decrease in cell viability was evident in the first 24 h
compared with control. In general, the combination of the
two agents exhibited greater cell toxicity compared with
each individual agent alone. However, using multiple com-
parison method (HSD), the difference between the com-
bination and single agents were not significant in the
WSU-WM and WSU-DLCL2 cells (p > 0.05). In the
WSU-FSCCL cells, the difference between the combin-
ation and RTX was significant (p = 0.0003 at 24 h; 0.0002
at 48 h; and 0.004 at 72 h) whereas the combination versus
2-CdA was not significant (p = 0.99-1.0).
Efficacy of R-2-CdA in the WSU-WM-SCID mouse xenograft
model
Experiment 1
As shown in Figure 3, all animals in the control group
were euthanized within the first 22 days of treatment. 2-
CdA treatment showed a modest but non-significant im-
provement in survival compared with control. This agent
was effective for a short period of time in delaying
tumor progression compared with control. However, tu-
mors grew rapidly once the disease progressed and all
remaining animals were euthanized within 30 days of
treatment. In contrast, in animals treated with RTX,
tumor development was delayed in one animal of the
RTX-treated group (day 45) and another animal survived
to the end of the experiment and was tumor-free. The
combination of the two agents was clearly more effective
(p = 0.01) compared with single agents and 2 of the 7 an-
imals within this group were tumor-free at the end of
the experiment.
Experiment 2
In this experiment, we tested a higher dose-intensity of
the R-2-CdA regimen. As summarized in Table 2, both
RTX and 2-CdA exhibited modest activity as single
agents even at higher doses. At a median tumor weight
in the control group of 700 mg, there was 30% and
36.9% tumor growth inhibition caused by RTX and 2-
CdA treatment, respectively (<42% is considered active).














Figure 1 Survival of patients treated with the R-2-CdA regimen (n = 13). Kaplan-Meier overall survival from end of therapy with R-2-CdA to
last follow up (censored) or death. Median survival is 7.9 years.
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with control. Activity was also modest by the log10Kill
measure (1.9 and 1.33 for RTX and 2-CdA, respectively).
None of the animals in the single agent-treated groups
survived to the end of the experiment, ie, all developed
tumors and were euthanized. However, in the combin-
ation group, all animals were tumor-free at the end of
the experiment (120 days) as confirmed by pathologic
examination at necropsy. There were also no treatment-
related deaths in this study using increased doses of both
RTX and 2-CdA.
Phenotypic analysis of residual WSU-WM xenograft tumors
following RTX therapy
In order to determine the effect of RTX therapy on the
WM phenotype, residual tumors (after RTX therapy)
were examined by flow cytometry. As shown in Figure 4A,
there was no significant change in WM phenotype in
RTX-treated animals compared with control, except for
CD20 and CD22 antigens. The RTX target antigen CD20
became undetectable in 97-98% of cells, whereas CD22
showed some increase in the RTX-treated tumors com-
pared with control (Figure 4A). CD20 antigen expressionbecame detectable again within a few days after comple-
tion of RTX therapy. By day 9 post-therapy, ~40% of
tumor cells were CD20 + (Figure 4B). To determine
whether CD20 negativity represented a subpopulation of
RTX-resistant cells or antigen masking, i.e. false negative,
additional experiments were conducted. Using anti-RTX
antibody (anti-C2B8 clone), we demonstrated that WSU-
WM xenograft tumor cells of RTX-treated animals were
positive for C2B8, indicating that RTX was still bound to
the CD20 antigen (Figure 5). These results indicate that
the reported “negative” expression of CD20 in RTX-
treated xenografts is due to the antigen being masked by
RTX rather than the lack of CD20 antigen expression.
RTX therapy increases dCK activity in WSU-WM tumors
dCK is a key enzyme for the intracellular phosphoryl-
ation of nucleoside analogues, in this case, 2-CdATP.
We therefore sought to determine if combining RTX
with 2-CdA has any impact on dCK activity. As shown
in Figure 6, dCK activity in WSU-WM tumors obtained
from control mice ranged from 34.7 to 389.26 pmoles/
mg/protein/min (Mean ± S.D. = 226 ± 153) and did not
increase with time. In contrast, dCK activity in tumors
AB
C
Figure 2 Effect of rituximab (RTX) and 2-CdA alone or in combination (combo) on lymphoma cell lines in vitro. Cell viability was
measured by 0.4% trypan blue exclusion assay over a 72 h incubation period [mean and standard error means (SEM)]. Cell lines used were: (A)
WSU-FSCCL (follicular lymphoma); (B) WSU-DLCL2 (diffuse large B-cell lymphoma); and (C) WSU-WM (Waldenström’s macroglobulinemia). Cells
were exposed to each agent at the beginning of culture (time 0) with 2-CdA at 50 nM, RTX 100 μg, or both agents at the same concentration.
*indicates significant difference compared with control (p < 0.05).
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Figure 3 Survival of WSU-WM-bearing ICR-SCID mice treated with 2-CdA, RTX alone or in combination. Log-Rank Test showing the
combination (RTX +2-CdA) to be statistically superior to single agents (p = 0.01007).
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the control and became statistically significant as the
number of RTX injections increased (RTX one injection =
669 ± 319, p = 0.128; RTX three injections = 743 ± 165,
p = 0.013; RTX five injections = 698 ± 13, p = 0.00004).
This suggests that multiple injections or a sequential
dosing schedule may be necessary to achieve the greatest
effect on dCK activity.
Modulation of p38MAPK and GSK3β by RTX and 2-CdA
Changes in the p38MAPK and GSK3β were evident after
the 3rd injection of mice carrying the WSU-WM tumors
with RTX and 2-CdA. There was a sustained activation
of p38MAPK (p-p38MAPK) in tumors of the RTX-
treated animals and a decrease in phosphorylated GSK3β
(Figure 7A). This finding suggested a relationship be-
tween p38MAPK and GSK3β which was investigated
further in vitro. Under different experimental conditions,
we induced activation of p38MAPK by RTX and 2-CdA
(for 48 h) then blocked it chemically by SB203580. Such
experiment revealed that chemical inhibition of RTX-
and 2-CdA-induced activation of p38MAPK significantly
reduced phosphorylation of GSK3β (Figure 7B). This ex-
periment indicated that GSK3β can be regulated byTable 2 Efficacy of rituximab and 2-CdA in the WSU-WM-SCID
Agent Dose/(mg/kg), schedule Route M
Control Diluent, QD × 5 i.v.
Rituximab 150 mg, QD × 5 i.v.
2-CdA 30 mg, QD × 5 s.c.
(RTX + 2-CdA) (150 + 30),QD × 5 (i.v. + s.c.)
Diluent Diluent, QD × 5 i.v.
(RTX + 2-CdA) (150 + 30),QD × 5 (i.v. + s.c.)p38MAPK in this tumor model. Together with the ani-
mal data, these results suggest that p38MAPK can be a
GSK3β kinase.
Discussion
Although low grade B-cell tumors in humans remain in-
curable, availability of alternative treatment regimens
have contributed to prolongation of survival of these pa-
tients. This observation is illustrated in our study where
there was 11 years lapse time in median age between
diagnosis (median age 48 years) and R-2-CdA treatment
(59 years, Table 1). Moreover, the median survival of our
patients from completion of R-2CdA treatment was
7.9 years (Figure 1). The R-2-CdA regimen exhibited im-
pressive activity as salvage regimen in our advanced-
stage, heavily pretreated patient population where 77%
of patients responded with a median duration of re-
sponse of 34 months.
Each individual agent in the R-2-CdA regimen indi-
vidually has activity in low grade B-cell tumors. When
used as salvage therapy in previously treated patients
with low grade (indolent) NHL, 2-CdA produced 35%
complete response (CR) and 54% partial response (PR)
rate [16]. In another study, the overall response ratexenograft model
ice T/C (%) T-C Days Log10 kill Cure
8 100 0 0 0/8
8 30 13 1.9 0/8
8 36.9 14 1.33 0/8
8 16.9 N/A N/A 8/8
Figure 4 Flow cytometric analysis of WSU-WM xenograft tumors. A. Phenotype of tumor cells in control (untreated) and following rituximab
therapy, B. CD20 expression in residual tumors removed at days 7 and 9 post completion of RTX therapy compared with day of completion of
therapy (day 0) and with tumors of untreated animals (untreated).
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2-CdA produced 25% CR and 60% PR [17]. Rituximab as
single agent, on the other hand produced 67% and 46%
ORR when given to previously untreated and as salvage
therapy for patients with follicular lymphoma (FL), re-
spectively [6]. In CLL/SLL, rituximab monotherapy up-
front produced 58% ORR [31].
Rituximab and 2-CdA have been administered in com-
bination as a two-agent regimen or in combination with
additional agents in low grade B-cell tumors. In one
study, the R-2-CdA regimen was given to patients with
Waldenstrom’s macrgolbulinemia (WM) where the
ORR was 89.6% without differences being observed
between previously treated and untreated patients
[23]. The ORR in this study however included minor
responses besides CR and PR. In another study, R-2-
CdA produced 15.4% CR and 53.8% PR (ORR =69.2%)
in relapsed/refractory patients with low grade NHL
[24]. 2-CdA in combination with oral cyclophospha-
mide therapy resulted in an overall response rateof 84% in previously untreated patients with WM
whereas 2-CdA/cyclophosphamide/RTX combination
resulted in an overall response of 94% [22]. It is pos-
sible that a 2-CdA/RTX combination may yield com-
parable response rates without the added toxicity of
cyclophosphamide [32]. This is supported by the
results of another study where there was no difference
in efficacy between cyclophosphamide plus 2-CdA com-
pared with 2-CdA alone in CLL/SLL [33]. Whether or not
the activity of R-2-CdA regimen is limited to the indolent
NHL still remains an open question. Our limited in vitro
study suggests that R-2-CdA may have activity in more ag-
gressive tumors like DLBCL albeit lower than that seen in
FL (Figure 2).
None of the clinical studies mentioned above ad-
dressed possible mechanisms of interaction between
RTX and 2-CdA, perhaps due to the limited availability
of patient samples for such investigation. In our study,
we utilized the WSU-WM-SCID mouse xenograft model
as a source of tumor tissue to investigate possible
Figure 5 Detailed analysis of CD20 expression in residual tumor cells following treatment of animals with rituximab. A1 – Isotype
control for CD 20; A2 – Isotype control for anti-rituximab (anti-C2B8); B1– CD 20, untreated animal (positive expression); B2 – Anti-C2B8, untreated
animal (negative expression); C1– CD 20, RTX-treated animal (negative expression); C2 – Anti-C2B8 in RTX-treated animal (positive expression).
Figure 6 Deoxycytidine kinase activity (dCK) in WSU-WM tumors removed from untreated SCID mice (control) or following 1, 3, or 5
injections of RTX as described in the Method section. Each bar represents mean and SEM of 3 animals.
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Figure 7 p38MAPK and GSK3β protein expression by Western blots in the WSU-WM model. A. Expression in xenograft tumors taken from
SCID mice following treatment with 1, 2 or 3 injections with rituximab, 2-CdA or the two agents (combo). 50 μg total tumor tissue lysates were
subjected to Western blot for detection of phospho-p38MAPK, phospho-GSK3β using GAPDH as a loading control; B. Effect of chemical inhibition
of p38MAPK on GSK3β expression in vitro. WSU-WM cells in culture were exposed to 2-CdA (50nM), RTX (100 μg), or combo (2-CdA + RTX). 48 h
later, DMSO (vehicle) or p-38MAPK inhibitor SB203580 (30 μM) were added and cultures were maintained for an additional 48 h. At the end of
incubation, lysates were collected and subjected to immunoblotting using GAPDH as loading control.
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first confirmed the activity of the R-2-CdA regimen in
this model (Figure 3) and demonstrated superior value
of the combination versus single agent (p = 0.01, Fig-
ure 3). We also demonstrated that increased dose-
intensity of the R-2-CdA regimen is feasible and can
produce higher and more durable responses. Two cycles
of the regimen eradicated the xenograft tumors in all an-
imals and were well tolerated (Table 2). This observation
suggests that higher number of treatment cycles in hu-
man, whenever possible, may produce more durable
remissions.
A key question in this study relates to the potential
mechanisms of interaction between RTX and 2-CdA.
We first analyzed the phenotype of residual WSU-WM
xenograft tumors following treatment with RTX. The
two molecules identified with RTX resistance (CD55 and
CD59 [34]) were brightly positive at baseline in the
WSU-WM tumors and were not changed significantly
after RTX treatment. However, the most remarkable
change in phenotype following RTX treatment was the
apparent negative expression of CD20 (Figure 4A).
CD20 expression became detectable slowly after RTX
treatment was terminated, as shown in Figure 4B.Within 9 days of therapy, CD20 expression was again
detectable by flow cytometry in 40% of cells. Using
RTX antibody, we proved that the apparent negative
expression is due to CD 20 antigen masking by RTX
(Figure 5). The return of CD20 expression within sev-
eral days supports the use of repeated doses of RTX
infusion in conjunction with chemotherapy.
The phenotypic studies nullified our previous hypoth-
esis that 2-CdA can eradicate a subpopulation of CD20
(−) B-cell lymphoma that are resistant to RTX hence
providing a mechanism of interaction between the 2
agents.
We next argued that enhancing dCK activity can be a
mechanism of interaction between RTX and 2-CdA. The
dCK enzyme is paramount in the deoxynucleoside
salvage pathway and in the activation of numerous
nucleoside analogues used in cancer and in antiviral
chemotherapy including 2-CdA. Reduction in dCK activ-
ity was a major cause of 2-CdA resistance [35]. As
shown in Figure 6, RTX treatment induced a 3 fold in-
crease in dCK activity within WSU-WM xenograft tu-
mors with increasing statistical significance as the
number injections increased. Although several factors
are involved in determining activity of 2-CdA against
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necessary step. The drug is phosphorylated by dCK and
accumulates in the cells as 2-chlorodeoxyadenosine tri-
phosphate (2-CdA TP) which is the active form [36].
The increase in dCK activity induced by RTX in the
xenograft tumors can be one mechanism by which RTX
enhances the activity of 2-CdA.
The mechanism by which RTX induces activation of
dCK remains elusive. However, we looked at impact of
RTX on other kinases relevant to cancer. RTX
treatment of WSU-WM-bearing SCID mice induced
sustained activation (phosphorylation) of p38MAPK
(p-p38MAPK) and dephosphorylation (activation) of
GSK3β (Figure 7A) suggesting a possible relationship
between these 2 kinases in this model. However, under
different experimental conditions in vitro, exposure
of WSU-WM cells to RTX and 2-CdA induced
phosphorylation of GSK3β. Chemical inhibition of
p38MAPK by SB203580 inhibited treatment-induced
phosphorylation of GSK3β (Figure 7). To our know-
ledge, this is the first evidence that GSK3β can be
regulated by p38MAPK.
GSK-3, a serine/threonine kinase plays an important
role in a variety of cellular processes such as cell pro-
liferation, microtubule dynamics, cell cycle and apop-
tosis [37]. GSK3β, the key component that regulates
canonical WNT/β-catenin and PI3K/Akt signaling
pathways, is commonly considered a tumor suppressor
in multiple cancers [38]. The activity of GSK3β can be
reduced by phosphorylation at Ser-9. Several kinases
are able to mediate this modification like p70S6,
p90RSK, Akt and PKC [39,40]. Dysregulation of
GSK3β has been implicated in many pathological
conditions in man. Within cancer, it was shown to
have varying, and sometimes opposing effects. For ex-
ample, GSK3β was shown to inhibit growth of prostate
cancer cells thus acting as a tumor suppressor [41]. In
contrast, GSK3β was shown to participate in cell
survival in pancreatic cancer hence behaving as a
tumor promoter [42]. Moreover, the kinase has dual
function where it can activate or inhibit apoptosis
[43]. The divergent functions of GSK3β appear to de-
pend on cell type, intracellular pathways triggered by
therapeutic agent(s) tested and the experimental con-
ditions. In fact this context-dependent biological effect
concept of therapeutic agents in cancer can be gener-
alized. One example is our observation of persistent
p38MAPK activation in RTX-treated WSU-WM-SCID
xenograft tumors (Figure 7A) which is in contradis-
tinction to previous reports where RTX caused
inhibition of p38MAPK in vitro in a diffuse large B-
cell lymphoma cell line [44,45]. Whether GSK3β,
p38MAPK, or other protein kinase(s), are involved in
dCK activation will require further investigation.Conclusions
In conclusion, R-2-CdA regimen can activate multiple
protein kinases known to contribute positively to anti-
cancer activity. There appears to be interaction between
these kinase pathways as demonstrated in the relationship
between p38MAPK and GSK3β. Such interaction can be
the basis for synergism between RTX and 2-CdA. Deter-
mining whether RTX-induced activation of dCK is medi-
ated by its phosphorylation and which kinase pathway
involved in such activation needs further investigation.
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